Filing Flows › Health Care earnings

Health Care earnings

648 Health Care companies by revenue, each with its latest quarter drawn from the SEC filing.

The largest: McKesson

• McKesson (MCK) Q2 FY27 · revenue $111.0B · +8% Y/Y
• Cencora (COR) Q3 FY26 · revenue $84.8B · +5% Y/Y
• Cardinal Health (CAH) Q1 FY27 · revenue $67.5B · +6% Y/Y
• Johnson & Johnson (JNJ) Q3 2026 · revenue $25.4B · +6% Y/Y
• ELI Lilly (LLY) Q3 2026 · revenue $24.4B · +39% Y/Y
• HCA Healthcare (HCA) Q3 2026 · revenue $19.8B · +4% Y/Y
• Merck (MRK) Q3 2026 · revenue $18.1B · +5% Y/Y
• AbbVie (ABBV) Q3 2026 · revenue $17.4B · +10% Y/Y
• Pfizer (PFE) Q3 2026 · revenue $16.6B · -0.4% Y/Y
• Bristol Myers Squibb (BMY) Q3 2026 · revenue $13.1B · +7% Y/Y
• Abbott Laboratories (ABT) Q3 2026 · revenue $13.0B · +14% Y/Y
• Amgen (AMGN) Q3 2026 · revenue $10.4B · +8% Y/Y
• Medtronic (MDT) Q1 FY27 · revenue $9.8B · +14% Y/Y
• Gilead Sciences (GILD) Q3 2026 · revenue $8.3B · +7% Y/Y
• Medline (MDLN) Q3 2026 · revenue $7.9B · +10% Y/Y
• 3M (MMM) Q3 2026 · revenue $6.6B · +1% Y/Y
• Stryker (SYK) Q3 2026 · revenue $6.5B · +8% Y/Y
• Tenet Healthcare (THC) Q3 2026 · revenue $5.6B · +6% Y/Y
• GE HealthCare Technologies (GEHC) Q3 2026 · revenue $5.5B · +7% Y/Y
• Boston Scientific (BSX) Q3 2026 · revenue $5.1B · +1% Y/Y
• Regeneron Pharmaceuticals (REGN) Q3 2026 · revenue $5.1B · +36% Y/Y
• Becton Dickinson (BDX) Q3 FY26 · revenue $5.0B · +5% Y/Y
• Universal Health Services (UHS) Q3 2026 · revenue $4.7B · +5% Y/Y
• Teva Pharmaceutical Industries (TEVA) Q3 2026 · revenue $4.4B · -2% Y/Y
• BrightSpring Health Services (BTSG) Q3 2026 · revenue $4.2B · +26% Y/Y
• Labcorp Holdings (LH) Q3 2026 · revenue $3.8B · +7% Y/Y
• Viatris (VTRS) Q3 2026 · revenue $3.7B · -0.3% Y/Y
• Davita (DVA) Q3 2026 · revenue $3.6B · +5% Y/Y
• Vertex Pharmaceuticals (VRTX) Q3 2026 · revenue $3.4B · +12% Y/Y
• Quest Diagnostics (DGX) Q3 2026 · revenue $3.1B · +10% Y/Y
• Intuitive Surgical (ISRG) Q3 2026 · revenue $3.0B · +22% Y/Y
• Baxter International (BAX) Q3 2026 · revenue $3.0B · +5% Y/Y
• Bausch Health Companies (BHC) Q3 2026 · revenue $2.9B · +10% Y/Y
• Biogen (BIIB) Q3 2026 · revenue $2.8B · +11% Y/Y
• Community Health Systems (CYH) Q3 2026 · revenue $2.8B · -11% Y/Y
• Zoetis (ZTS) Q3 2026 · revenue $2.4B · -1% Y/Y
• Zimmer Biomet Holdings (ZBH) Q3 2026 · revenue $2.1B · +3% Y/Y
• Solventum (SOLV) Q3 2026 · revenue $1.9B · -7% Y/Y
• BeOne Medicines (ONC) Q3 2026 · revenue $1.9B · +34% Y/Y
• Edwards Lifesciences (EW) Q3 2026 · revenue $1.7B · +10% Y/Y
• Ardent Health (ARDT) Q3 2026 · revenue $1.6B · +3% Y/Y
• Encompass Health (EHC) Q3 2026 · revenue $1.6B · +9% Y/Y
• Steris (STE) Q2 FY27 · revenue $1.6B · +9% Y/Y
• Organon (OGN) Q3 2026 · revenue $1.6B · -2% Y/Y
• agilon health (AGL) Q3 2026 · revenue $1.5B · +6% Y/Y
• Pacs Group (PACS) Q3 2026 · revenue $1.5B · +12% Y/Y
• Option Care Health (OPCH) Q3 2026 · revenue $1.5B · +4% Y/Y
• Ensign Group (ENSG) Q3 2026 · revenue $1.5B · +14% Y/Y
• Alnylam Pharmaceuticals (ALNY) Q3 2026 · revenue $1.5B · +17% Y/Y
• ResMed (RMD) Q1 FY27 · revenue $1.4B · +6% Y/Y
• Bausch & Lomb (BLCO) Q3 2026 · revenue $1.4B · +7% Y/Y
• Herbalife (HLF) Q3 2026 · revenue $1.4B · +6% Y/Y
• DexCom (DXCM) Q3 2026 · revenue $1.3B · +11% Y/Y
• Moderna (MRNA) Q3 2026 · revenue $1.3B · +29% Y/Y
• Elanco Animal Health (ELAN) Q3 2026 · revenue $1.3B · +11% Y/Y
• Jazz Pharmaceuticals (JAZZ) Q3 2026 · revenue $1.2B · +10% Y/Y
• Idexx Laboratories (IDXX) Q3 2026 · revenue $1.2B · +10% Y/Y
• Neurocrine Biosciences (NBIX) Q3 2026 · revenue $1.1B · +41% Y/Y
• Cooper Companies (COO) Q3 FY26 · revenue $1.1B · +0.6% Y/Y
• BioMarin Pharmaceutical (BMRN) Q3 2026 · revenue $1.0B · +32% Y/Y
• Align Technology (ALGN) Q3 2026 · revenue $1.0B · +2% Y/Y
• Perrigo (PRGO) Q3 2026 · revenue $988.6M · -5% Y/Y
• Acadia Healthcare Company (ACHC) Q3 2026 · revenue $895.3M · +5% Y/Y
• West Pharmaceutical Services (WST) Q3 2026 · revenue $874.5M · +9% Y/Y
• Amneal Pharmaceuticals (AMRX) Q3 2026 · revenue $862.7M · +10% Y/Y
• Surgery Partners (SGRY) Q2 2026 · revenue $848.9M · +3% Y/Y
• MiniMed Group (MMED) Q2 2026 · revenue $843.0M · +17% Y/Y
• Insulet (PODD) Q3 2026 · revenue $842.0M · +19% Y/Y
• Dentsply Sirona (XRAY) Q3 2026 · revenue $836.0M · -8% Y/Y
• United Therapeutics (UTHR) Q3 2026 · revenue $832.5M · +4% Y/Y
• Natera (NTRA) Q3 2026 · revenue $794.0M · +34% Y/Y
• Globus Medical (GMED) Q3 2026 · revenue $763.7M · -0.7% Y/Y
• Hims & Hers Health (HIMS) Q2 2026 · revenue $753.2M · +38% Y/Y
• AdaptHealth (AHCO) Q3 2026 · revenue $745.6M · +11% Y/Y
• Brookdale Senior Living (BKD) Q3 2026 · revenue $712.1M · -12% Y/Y
• Envista Holdings (NVST) Q3 2026 · revenue $691.5M · +3% Y/Y
• Fortrea Holdings (FTRE) Q3 2026 · revenue $691.5M · -1% Y/Y
• Chemed (CHE) Q3 2026 · revenue $690.9M · +11% Y/Y
• Royalty Pharma (RPRX) Q3 2026 · revenue $690.1M · +13% Y/Y
• Nurix Therapeutics (NRIX) Q3 FY26 · revenue $673.1M · 85× Y/Y
• Aveanna Healthcare Holdings (AVAH) Q2 2026 · revenue $670.5M · +14% Y/Y
• Exelixis (EXEL) Q3 2026 · revenue $658.7M · +10% Y/Y
• Privia Health Group (PRVA) Q3 2026 · revenue $657.0M · +13% Y/Y
• RadNet (RDNT) Q2 2026 · revenue $622.7M · +25% Y/Y
• Concentra Group Holdings Parent (CON) Q3 2026 · revenue $622.1M · +9% Y/Y
• QuidelOrtho (QDEL) Q3 2026 · revenue $618.9M · -12% Y/Y
• Teladoc Health (TDOC) Q3 2026 · revenue $605.1M · -3% Y/Y
• Teleflex (TFX) Q3 2026 · revenue $567.8M · +0.1% Y/Y
• ICU Medical (ICUI) Q3 2026 · revenue $560.4M · +4% Y/Y
• Enovis (ENOV) Q3 2026 · revenue $558.7M · +2% Y/Y
• MSA Safety (MSA) Q3 2026 · revenue $536.4M · +14% Y/Y
• Insmed (INSM) Q3 2026 · revenue $524.4M · +268% Y/Y
• Keenova Therapeutics Q2 2026 · revenue $517.2M · +96% Y/Y
• Pediatrix Medical Group (MD) Q3 2026 · revenue $501.4M · +2% Y/Y
• National Vision Holdings (EYE) Q2 2026 · revenue $498.8M · +2% Y/Y
• Halozyme Therapeutics (HALO) Q3 2026 · revenue $493.0M · +39% Y/Y
• Alkermes (ALKS) Q3 2026 · revenue $480.1M · +22% Y/Y
• Healthcare Services Group (HCSG) Q3 2026 · revenue $479.6M · +3% Y/Y
• LifeStance Health Group (LFST) Q3 2026 · revenue $455.9M · +25% Y/Y
• Integer Holdings (ITGR) Q3 2026 · revenue $449.7M · -4% Y/Y
• Madrigal Pharmaceuticals (MDGL) Q3 2026 · revenue $431.3M · +50% Y/Y
• Merit Medical Systems (MMSI) Q3 2026 · revenue $416.2M · +8% Y/Y
• Integra Lifesciences Holdings (IART) Q3 2026 · revenue $411.2M · +2% Y/Y
• Penumbra (PEN) Q3 2026 · revenue $410.1M · +16% Y/Y
• National Healthcare (NHC) Q3 2026 · revenue $408.0M · +7% Y/Y
• LivaNova (LIVN) Q3 2026 · revenue $393.1M · +10% Y/Y
• Lantheus Holdings (LNTH) Q3 2026 · revenue $389.9M · +2% Y/Y
• Addus HomeCare (ADUS) Q3 2026 · revenue $387.7M · +7% Y/Y
• Phibro Animal Health (PAHC) Q1 FY27 · revenue $386.8M · +6% Y/Y
• P3 Health Partners (PIII) Q2 2026 · revenue $386.4M · +9% Y/Y
• Sarepta Therapeutics (SRPT) Q3 2026 · revenue $381.4M · -4% Y/Y
• Guardant Health (GH) Q3 2026 · revenue $361.0M · +36% Y/Y
• PTC Therapeutics (PTCT) Q3 2026 · revenue $357.8M · +70% Y/Y
• Haemonetics (HAE) Q2 FY27 · revenue $357.8M · +9% Y/Y
• Indivior Pharmaceuticals (INDV) Q3 2026 · revenue $356.0M · +13% Y/Y
• BridgeBio Pharma (BBIO) Q3 2026 · revenue $353.2M · +193% Y/Y
• Curaleaf Holdings (CURLF) Q3 2026 · revenue $352.6M · +11% Y/Y
• Acadia Pharmaceuticals (ACAD) Q3 2026 · revenue $342.3M · +23% Y/Y
• Progyny (PGNY) Q3 2026 · revenue $341.3M · +9% Y/Y
• Corcept Therapeutics (CORT) Q3 2026 · revenue $340.5M · +64% Y/Y
• Prestige Consumer Healthcare (PBH) Q2 FY27 · revenue $336.3M · +23% Y/Y
• Conmed (CNMD) Q3 2026 · revenue $335.6M · -0.7% Y/Y
• Sotera Health (SHC) Q3 2026 · revenue $324.9M · +4% Y/Y
• MeiraGTx Holdings (MGTX) Q2 2026 · revenue $321.4M · 87× Y/Y
• Nu Skin Enterprises (NUS) Q3 2026 · revenue $311.0M · -15% Y/Y
• Pennant Group (PNTG) Q3 2026 · revenue $302.3M · +32% Y/Y
• Bio-Techne (TECH) Q1 FY27 · revenue $299.7M · +5% Y/Y
• ANI Pharmaceuticals (ANIP) Q3 2026 · revenue $290.8M · +28% Y/Y
• Kiniksa Pharmaceuticals International (KNSA) Q3 2026 · revenue $286.0M · +58% Y/Y
• Tandem Diabetes Care (TNDM) Q3 2026 · revenue $283.7M · +14% Y/Y
• Caris Life Sciences (CAI) Q3 2026 · revenue $275.4M · +27% Y/Y
• Protagonist Therapeutics (PTGX) Q3 2026 · revenue $274.4M · 58× Y/Y
• Embecta (EMBC) Q3 FY26 · revenue $271.7M · -8% Y/Y
• Harmony Biosciences Holdings (HRMY) Q3 2026 · revenue $268.9M · +12% Y/Y
• Ionis Pharmaceuticals (IONS) Q2 2026 · revenue $267.9M · -41% Y/Y
• InnovAge Holding (INNV) Q1 FY27 · revenue $264.8M · +12% Y/Y
• Lumexa Imaging Holdings (LMRI) Q2 2026 · revenue $264.2M · +5% Y/Y
• Axsome Therapeutics (AXSM) Q3 2026 · revenue $259.7M · +52% Y/Y
• Tilray Brands (TLRY) Q1 FY27 · revenue $257.1M · +23% Y/Y
• Warby Parker (WRBY) Q3 2026 · revenue $244.7M · +10% Y/Y
• TG Therapeutics (TGTX) Q2 2026 · revenue $240.3M · +70% Y/Y
• Vir Biotechnology (VIR) Q2 2026 · revenue $238.9M · 197× Y/Y
• Trulieve Cannabis (TRLV) Q3 2026 · revenue $230.2M · -20% Y/Y
• Supernus Pharmaceuticals (SUPN) Q3 2026 · revenue $226.8M · +18% Y/Y
• Travere Therapeutics (TVTX) Q3 2026 · revenue $224.6M · +36% Y/Y
• Usana Health Sciences (USNA) Q2 2026 · revenue $223.3M · -5% Y/Y
• Neogen (NEOG) Q1 FY27 · revenue $222.8M · +6% Y/Y
• U S Physical Therapy (USPH) Q3 2026 · revenue $222.6M · +13% Y/Y
• iRhythm Holdings (IRTC) Q3 2026 · revenue $221.6M · +15% Y/Y
• Alphatec Holdings (ATEC) Q3 2026 · revenue $221.2M · +13% Y/Y
• Collegium Pharmaceutical (COLL) Q3 2026 · revenue $216.3M · +3% Y/Y
• Glaukos (GKOS) Q3 2026 · revenue $211.0M · +58% Y/Y
• Orthofix Medical (OFIX) Q2 FY26 · revenue $210.9M · +4% Y/Y
• Sonida Senior Living (SNDA) Q3 2026 · revenue $210.2M · +114% Y/Y
• Repligen (RGEN) Q3 2026 · revenue $209.3M · +11% Y/Y
• Vireo Growth (VREOF) Q2 2026 · revenue $209.3M · +335% Y/Y
• Amphastar Pharmaceuticals (AMPH) Q3 2026 · revenue $207.6M · +8% Y/Y
• Inspire Medical Systems (INSP) Q3 2026 · revenue $206.7M · -8% Y/Y
• TransMedics Group (TMDX) Q3 2026 · revenue $203.0M · +41% Y/Y
• Cadre Holdings (CDRE) Q3 2026 · revenue $202.9M · +30% Y/Y
• Myriad Genetics (MYGN) Q3 2026 · revenue $202.7M · -2% Y/Y
• Revolution Medicines (RVMD) Q3 2026 · revenue $197.6M
• Tarsus Pharmaceuticals (TARS) Q3 2026 · revenue $194.6M · +64% Y/Y
• NovoCure (NVCR) Q3 2026 · revenue $193.4M · +16% Y/Y
• Mirum Pharmaceuticals (MIRM) Q3 2026 · revenue $185.7M · +40% Y/Y
• Biocryst Pharmaceuticals (BCRX) Q3 2026 · revenue $180.3M · +13% Y/Y
• Pacira BioSciences (PCRX) Q3 2026 · revenue $176.7M · -2% Y/Y
• Ultragenyx Pharmaceutical (RARE) Q3 2026 · revenue $173.0M · +8% Y/Y
• UFP Technologies (UFPT) Q3 2026 · revenue $172.4M · +12% Y/Y
• Liquidia (LQDA) Q2 2026 · revenue $171.7M · 19× Y/Y
• Starling Oncology (STLN) Q3 2026 · revenue $169.8M · +24% Y/Y
• Alector (ALEC) Q3 2026 · revenue $162.9M · 50× Y/Y
• AtriCure (ATRC) Q3 2026 · revenue $154.4M · +15% Y/Y
• Veracyte (VCYT) Q3 2026 · revenue $151.8M · +15% Y/Y
• Arcutis Biotherapeutics (ARQT) Q3 2026 · revenue $143.9M · +45% Y/Y
• Bioventus (BVS) Q3 2026 · revenue $142.4M · +3% Y/Y
• Adma Biologics (ADMA) Q3 2026 · revenue $141.1M · +5% Y/Y
• CareDx (CDNA) Q3 2026 · revenue $139.4M · +39% Y/Y
• Ironwood Pharmaceuticals (IRWD) Q3 2026 · revenue $133.0M · +9% Y/Y
• Ardelyx (ARDX) Q3 2026 · revenue $127.7M · +16% Y/Y
• Krystal Biotech (KRYS) Q3 2026 · revenue $127.3M · +30% Y/Y
• Ascend Wellness Holdings (AAWH) Q2 2026 · revenue $126.1M · -0.9% Y/Y
• Artivion (AORT) Q3 2026 · revenue $123.8M · +9% Y/Y
• BillionToOne (BLLN) Q3 2026 · revenue $123.0M · +47% Y/Y
• Iovance Biotherapeutics (IOVA) Q3 2026 · revenue $121.5M · +80% Y/Y
• Twist Bioscience (TWST) Q3 FY26 · revenue $118.4M · +23% Y/Y
• Natures Sunshine Products (NATR) Q3 2026 · revenue $116.6M · -9% Y/Y
• Xencor (XNCR) Q3 2026 · revenue $116.5M · +455% Y/Y
• GeneDx Holdings (WGS) Q2 2026 · revenue $114.4M · +11% Y/Y
• Emergent BioSolutions (EBS) Q3 2026 · revenue $110.0M · -52% Y/Y
• Century Therapeutics (IPSC) Q1 2025 · revenue $109.2M · 128× Y/Y
• Zai Lab (ZLAB) Q3 2026 · revenue $108.2M · -7% Y/Y
• Xeris Biopharma Holdings (XERS) Q3 2026 · revenue $107.2M · +44% Y/Y
• Innoviva (INVA) Q3 2026 · revenue $106.1M · -2% Y/Y
• Castle Biosciences (CSTL) Q3 2026 · revenue $102.9M · +24% Y/Y
• Immunocore Holdings (IMCR) Q3 2026 · revenue $102.2M · -1% Y/Y
• CorMedix (CRMD) Q2 2026 · revenue $101.9M · +156% Y/Y
• Mannkind (MNKD) Q3 2026 · revenue $101.9M · +24% Y/Y
• Procept BioRobotics (PRCT) Q3 2026 · revenue $98.3M · +18% Y/Y
• Viskase Holdings (VISK) Q3 2026 · revenue $95.3M · +4% Y/Y
• Inogen (INGN) Q2 2026 · revenue $95.1M · +3% Y/Y
• Rhythm Pharmaceuticals (RYTM) Q3 2026 · revenue $92.1M · +80% Y/Y
• Tactile Systems Technology (TCMD) Q3 2026 · revenue $91.9M · +7% Y/Y
• Omada Health (OMDA) Q3 2026 · revenue $91.3M · +34% Y/Y
• Fulgent Genetics (FLGT) Q3 2026 · revenue $90.4M · +8% Y/Y
• UroGen Pharma (URGN) Q3 2026 · revenue $89.0M · +224% Y/Y
• Accuray (ARAY) Q1 FY27 · revenue $86.5M · -8% Y/Y
• Vericel (VCEL) Q3 2026 · revenue $85.4M · +26% Y/Y
• Phathom Pharmaceuticals (PHAT) Q3 2026 · revenue $84.7M · +71% Y/Y
• Cronos Group (CRON) Q3 2026 · revenue $83.9M · +72% Y/Y
• Adaptive Biotechnologies (ADPT) Q3 2026 · revenue $83.9M · -11% Y/Y
• Aurinia Pharmaceuticals (AUPH) Q3 2026 · revenue $83.7M · +14% Y/Y
• Staar Surgical (STAA) Q3 2026 · revenue $83.4M · -12% Y/Y
• Syndax Pharmaceuticals (SNDX) Q3 2026 · revenue $83.3M · +82% Y/Y
• Angiodynamics (ANGO) Q1 FY27 · revenue $80.9M · +7% Y/Y
• Rigel Pharmaceuticals (RIGL) Q3 2026 · revenue $80.9M · +16% Y/Y
• Viemed Healthcare (VMD) Q3 2026 · revenue $80.7M · +12% Y/Y
• Ligand Pharmaceuticals (LGND) Q3 2026 · revenue $78.7M · -32% Y/Y
• Evolus (EOLS) Q3 2026 · revenue $78.0M · +13% Y/Y
• Axogen (AXGN) Q3 2026 · revenue $75.8M · +26% Y/Y
• Arrowhead Pharmaceuticals (ARWR) Q3 FY26 · revenue $75.3M · +171% Y/Y
• Precigen (PGEN) Q3 2026 · revenue $74.1M · 25× Y/Y
• DocGo (DCGO) Q2 2026 · revenue $73.4M · -9% Y/Y
• Orthopediatrics (KIDS) Q3 2026 · revenue $72.7M · +19% Y/Y
• Establishment Labs Holdings (ESTA) Q3 2026 · revenue $72.0M · +34% Y/Y
• Canopy Growth (CGC) Q2 FY27 · revenue C$99.5M · +20% Y/Y
• Harrow (HROW) Q2 2026 · revenue $70.7M · +11% Y/Y
• Jushi Holdings (JUSH) Q3 2026 · revenue $70.5M · +7% Y/Y
• Black Diamond Therapeutics (BDTX) Q1 2025 · revenue $70.0M
• Vanda Pharmaceuticals (VNDA) Q3 2026 · revenue $69.8M · +24% Y/Y
• SkinHealth Systems (SKIN) Q3 2026 · revenue $69.2M · -2% Y/Y
• Novavax (NVAX) Q3 2026 · revenue $68.3M · -3% Y/Y
• Lemaitre Vascular (LMAT) Q3 2026 · revenue $68.0M · +11% Y/Y
• Park Dental Partners (PARK) Q2 2026 · revenue $66.2M · +5% Y/Y
• Opko Health (OPK) Q3 2026 · revenue $65.4M · +16% Y/Y
• Kymera Therapeutics (KYMR) Q2 2026 · revenue $65.0M · +466% Y/Y
• Schrodinger (SDGR) Q3 2026 · revenue $64.5M · +19% Y/Y
• Heartflow (HTFL) Q2 2026 · revenue $64.1M · +48% Y/Y
• Mimedx Group (MDXG) Q3 2026 · revenue $62.3M · -45% Y/Y
• Talkspace Q2 2026 · revenue $61.7M · +14% Y/Y
• Geron (GERN) Q3 2026 · revenue $60.2M · +27% Y/Y
• Eton Pharmaceuticals (ETON) Q3 2026 · revenue $57.9M · +158% Y/Y
• Cerus (CERS) Q3 2026 · revenue $57.7M · +10% Y/Y
• Si-Bone (SIBN) Q3 2026 · revenue $55.7M · +14% Y/Y
• Agios Pharmaceuticals (AGIO) Q3 2026 · revenue $55.4M · +330% Y/Y
• Puma Biotechnology (PBYI) Q3 2026 · revenue $55.1M · +1% Y/Y
• Monte Rosa Therapeutics (GLUE) Q3 2026 · revenue $54.4M · +326% Y/Y
• Tango Therapeutics (TNGX) Q3 2025 · revenue $53.8M · +364% Y/Y
• ImmunityBio (IBRX) Q2 2026 · revenue $51.2M · +94% Y/Y
• Cryoport (CYRX) Q3 2026 · revenue $50.2M · +14% Y/Y
• Lakeland Industries (LAKE) Q2 FY27 · revenue $50.1M · -4% Y/Y
• CapForce (CFOR) Q2 2026 · revenue $50.0M · 12× Y/Y
• SBC Medical Group Holdings (SBC) Q2 2026 · revenue $49.2M · +13% Y/Y
• Treace Medical Concepts (TMCI) Q3 2026 · revenue $48.3M · -4% Y/Y
• Cytokinetics (CYTK) Q3 2026 · revenue $47.6M · 25× Y/Y
• LifeMD (LFMD) Q2 2026 · revenue $47.3M · -4% Y/Y
• Maravai Lifesciences Holdings (MRVI) Q3 2026 · revenue $45.9M · +10% Y/Y
• Autolus Therapeutics (AUTL) Q2 2026 · revenue $45.7M · +118% Y/Y
• Organogenesis Holdings (ORGO) Q3 2026 · revenue $45.5M · -70% Y/Y
• Nuvation Bio (NUVB) Q3 2026 · revenue $45.0M · +243% Y/Y
• biote (BTMD) Q3 2026 · revenue $43.3M · -10% Y/Y
• Lifevantage (LFVN) Q2 2026 · revenue $42.4M · -23% Y/Y
• Neuronetics (STIM) Q3 2026 · revenue $42.0M · +12% Y/Y
• Marimed (MRMD) Q2 2026 · revenue $41.9M · +6% Y/Y
• Siga Technologies (SIGA) Q2 2026 · revenue $41.0M · -50% Y/Y
• Keros Therapeutics (KROS) Q3 2026 · revenue $40.0M · +183% Y/Y
• Amarin (AMRN) Q3 2026 · revenue $39.5M · -20% Y/Y
• Zevra Therapeutics (ZVRA) Q3 2026 · revenue $37.8M · +45% Y/Y
• ARS Pharmaceuticals (SPRY) Q3 2026 · revenue $37.7M · +16% Y/Y
• Heron Therapeutics (HRTX) Q2 2026 · revenue $37.7M · +1% Y/Y
• InfuSystem Holdings (INFU) Q3 2026 · revenue $37.6M · +3% Y/Y
• Grail (GRAL) Q3 2026 · revenue $37.5M · +4% Y/Y
• Akebia Therapeutics (AKBA) Q3 2026 · revenue $36.9M · -37% Y/Y
• vTv Therapeutics (VTVT) Q1 2026 · revenue $36.8M
• Beta Bionics (BBNX) Q3 2026 · revenue $35.5M · +30% Y/Y
• Actinium Pharmaceuticals (ATNM) Q2 2026 · revenue $35.0M
• Natural Alternatives International (NAII) Q4 FY26 · revenue $34.5M · +2% Y/Y
• Bicycle Therapeutics (BCYC) Q3 2026 · revenue $34.1M · +190% Y/Y
• Outset Medical (OM) Q3 2026 · revenue $33.6M · +14% Y/Y
• Karyopharm Therapeutics (KPTI) Q2 2026 · revenue $33.4M · -12% Y/Y
• Gyre Therapeutics (GYRE) Q3 2026 · revenue $32.9M · +0.7% Y/Y
• Macrogenics (MGNX) Q2 2026 · revenue $32.8M · +378% Y/Y
• Butterfly Network (BFLY) Q3 2026 · revenue $32.6M · +52% Y/Y
• Elite Pharmaceuticals (ELTP) Q1 FY27 · revenue $32.4M · -20% Y/Y
• Airsculpt Technologies (AIRS) Q3 2026 · revenue $31.9M · -9% Y/Y
• Agenus (AGEN) Q3 2026 · revenue $31.5M · +4% Y/Y
• Kestra Medical Technologies (KMTS) Q1 FY27 · revenue $31.0M · +60% Y/Y
• Orasure Technologies (OSUR) Q2 2026 · revenue $30.6M · -2% Y/Y
• Anika Therapeutics (ANIK) Q3 2026 · revenue $30.6M · +10% Y/Y
• Ceribell (CBLL) Q3 2026 · revenue $29.3M · +30% Y/Y
• Delcath Systems (DCTH) Q2 2026 · revenue $29.1M · +21% Y/Y
• Omeros (OMER) Q2 2026 · revenue $28.5M
• Biolife Solutions (BLFS) Q2 2026 · revenue $28.5M · +22% Y/Y
• Sanara MedTech (SMTI) Q2 2026 · revenue $28.1M · +9% Y/Y
• Niagen Bioscience (NAGE) Q3 2026 · revenue $27.2M · -20% Y/Y
• Zentalis Pharmaceuticals (ZNTL) Q4 2024 · revenue $26.9M
• Septerna (SEPN) Q2 2026 · revenue $26.7M · 225× Y/Y
• Mannatech (MTEX) Q2 2026 · revenue $26.6M · +4% Y/Y
• Fitlife Brands (FTLF) Q2 2026 · revenue $26.5M · +65% Y/Y
• Avita Medical (RCEL) Q3 2026 · revenue $26.1M · +53% Y/Y
• Viridian Therapeutics (VRDN) Q3 2026 · revenue $25.8M · -64% Y/Y
• Personalis (PSNL) Q3 2026 · revenue $25.6M · +77% Y/Y
• Lifecore Biomedical (LFCR) Q1 FY27 · revenue $25.3M · -19% Y/Y
• Crinetics Pharmaceuticals Q2 2026 · revenue $25.1M · 24× Y/Y
• Sight Sciences (SGHT) Q3 2026 · revenue $24.9M · +25% Y/Y
• RxSight (RXST) Q3 2026 · revenue $24.6M · -19% Y/Y
• Iradimed (IRMD) Q3 2026 · revenue $24.2M · +14% Y/Y
• Biodesix (BDSX) Q3 2026 · revenue $24.0M · +10% Y/Y
• Verastem (VSTM) Q3 2026 · revenue $24.0M · +114% Y/Y
• Xtant Medical Holdings (XTNT) Q2 2026 · revenue $23.0M · -35% Y/Y
• Pulmonx (LUNG) Q3 2026 · revenue $22.8M · +6% Y/Y
• NeuroPace (NPCE) Q2 2026 · revenue $22.8M · +17% Y/Y
• Kura Oncology (KURA) Q2 2026 · revenue $20.9M · +36% Y/Y
• Theravance Biopharma (TBPH) Q2 2026 · revenue $20.7M · -21% Y/Y
• Pro DEX (PDEX) Q1 FY27 · revenue $20.6M · +11% Y/Y
• Ginkgo Bioworks Holdings (DNA) Q2 2026 · revenue $20.2M · -48% Y/Y
• Maze Therapeutics (MAZE) Q1 2026 · revenue $20.0M
• Rapport Therapeutics (RAPP) Q1 2026 · revenue $20.0M
• Exagen (XGN) Q2 2026 · revenue $19.9M · +16% Y/Y
• Protalix BioTherapeutics (PLX) Q2 2026 · revenue $19.9M · +27% Y/Y
• Electromed (ELMD) Q4 FY26 · revenue $19.4M · +12% Y/Y
• Standard Biotools (LAB) Q3 2026 · revenue $19.4M · -0.9% Y/Y
• Tela Bio (TELA) Q2 2026 · revenue $19.3M · -4% Y/Y
• ADC Therapeutics SA (ADCT) Q2 2026 · revenue $19.2M · +2% Y/Y
• NewAmsterdam Pharma Co N.V. (NAMS) Q3 2026 · revenue $19.2M · 55× Y/Y
• Cosmos Health (COSM) Q2 2026 · revenue $19.0M · +29% Y/Y
• Carlsmed (CARL) Q2 2026 · revenue $18.9M · +57% Y/Y
• Fortress Biotech (FBIO) Q2 2026 · revenue $18.7M · +14% Y/Y
• Xilio Therapeutics (XLO) Q2 2026 · revenue $18.7M · +131% Y/Y
• Alpha Pro Tech (APT) Q2 2026 · revenue $18.7M · +12% Y/Y
• Recursion Pharmaceuticals (RXRX) Q3 2026 · revenue $18.6M · +258% Y/Y
• Journey Medical (DERM) Q2 2026 · revenue $18.5M · +23% Y/Y
• Arcturus Therapeutics Holdings (ARCT) Q3 2026 · revenue $18.3M · +7% Y/Y
• Fennec Pharmaceuticals (FENC) Q2 2026 · revenue $17.9M · +85% Y/Y
• Rockwell Medical (RMTI) Q2 2026 · revenue $17.8M · +11% Y/Y
• Denali Therapeutics (DNLI) Q3 2026 · revenue $17.8M
• Lensar (LNSR) Q2 2026 · revenue $16.5M · +18% Y/Y
• Shoulder Innovations (SI) Q3 2026 · revenue $16.2M · +38% Y/Y
• Aytu Biopharma (AYTU) Q4 FY26 · revenue $16.1M · +6% Y/Y
• Foghorn Therapeutics (FHTX) Q2 2026 · revenue $16.1M · +113% Y/Y
• Mobia Medical (MOBI) Q3 2026 · revenue $15.6M · +73% Y/Y
• Pelthos Therapeutics (PTHS) Q2 2026 · revenue $15.6M
• Champions Oncology (CSBR) Q1 FY27 · revenue $15.2M · +9% Y/Y
• Enanta Pharmaceuticals (ENTA) Q3 FY26 · revenue $14.4M · -22% Y/Y
• Coherus Oncology (CHRS) Q2 2026 · revenue $14.3M · +40% Y/Y
• Invivyd (IVVD) Q2 2026 · revenue $14.3M · +21% Y/Y
• Apyx Medical (APYX) Q3 2026 · revenue $14.0M · +9% Y/Y
• SS Innovations International (SSII) Q2 2026 · revenue $13.9M · +39% Y/Y
• CVRx (CVRX) Q3 2026 · revenue $13.8M · -6% Y/Y
• Tonix Pharmaceuticals Holding (TNXP) Q2 2026 · revenue $13.5M · +578% Y/Y
• Ocular Therapeutix (OCUL) Q2 2026 · revenue $13.5M · +0.1% Y/Y
• Assembly Biosciences (ASMB) Q2 2026 · revenue $13.4M · +39% Y/Y
• Wave Life Sciences (WVE) Q3 2026 · revenue $13.2M · +73% Y/Y
• Alpha Teknova (TKNO) Q3 2026 · revenue $12.7M · +22% Y/Y
• Crispr Therapeutics AG (CRSP) Q3 2026 · revenue $12.7M · 14× Y/Y
• Iridex (IRIX) Q2 2026 · revenue $12.6M · -7% Y/Y
• Apnimed (APMD) Q2 2026 · revenue $12.1M · -29% Y/Y
• ClearPoint Neuro (CLPT) Q3 2026 · revenue $12.1M · +36% Y/Y
• Koru Medical Systems (KRMD) Q2 2026 · revenue $12.0M · +18% Y/Y
• Biofrontera (BFRI) Q2 2026 · revenue $12.0M · +33% Y/Y
• Editas Medicine (EDIT) Q2 2026 · revenue $11.9M · +232% Y/Y
• Myomo (MYO) Q2 2026 · revenue $11.7M · +21% Y/Y
• TriSalus Life Sciences (TLSI) Q2 2026 · revenue $11.4M · +2% Y/Y
• Abeona Therapeutics (ABEO) Q2 2026 · revenue $11.4M · 28× Y/Y
• Stoke Therapeutics (STOK) Q3 2026 · revenue $11.3M · +6% Y/Y
• Lexicon Pharmaceuticals (LXRX) Q3 2026 · revenue $11.2M · -21% Y/Y
• Vaso (VASO) Q2 2026 · revenue $11.2M · -44% Y/Y
• Capricor Therapeutics (CAPR) Q4 2024 · revenue $11.1M · -8% Y/Y
• Pyxis Oncology (PYXS) Q4 2025 · revenue $11.0M
• Precision Biosciences (DTIL) Q3 FY26 · revenue $10.8M · 374× Y/Y
• Vaxart (VXRT) Q3 2026 · revenue $10.6M · -85% Y/Y
• Vera Therapeutics (VERA) Q3 2026 · revenue $10.3M
• Ideaya Biosciences (IDYA) Q3 2026 · revenue $10.2M · -95% Y/Y
• Nektar Therapeutics (NKTR) Q2 2026 · revenue $10.1M · -9% Y/Y
• Zenas BioPharma (ZBIO) Q3 2026 · revenue $10.0M
• Evommune (EVMN) Q3 2025 · revenue $10.0M
• Zomedica (ZOMDF) Q3 2026 · revenue $9.9M · +22% Y/Y
• Sutro Biopharma (STRO) Q2 2026 · revenue $9.8M · -85% Y/Y
• Profound Medical (PROF) Q3 2026 · revenue $9.8M · +86% Y/Y
• Edap TMS SA (FOCL) Q3 2026 · revenue $9.8M · +26% Y/Y
• Integrated Biopharma (INBP) Q4 FY26 · revenue $9.8M · -31% Y/Y
• Sanuwave Health (SNWV) Q2 2026 · revenue $9.7M · -3% Y/Y
• electroCore (ECOR) Q3 2026 · revenue $9.7M · +12% Y/Y
• Cytosorbents (CTSO) Q2 2026 · revenue $9.6M · +0.2% Y/Y
• Janux Therapeutics (JANX) Q3 2026 · revenue $9.3M · -7% Y/Y
• Sunshine Biopharma (SBFM) Q2 2026 · revenue $9.3M · -2% Y/Y
• Gossamer Bio (GOSS) Q2 2026 · revenue $9.2M · -20% Y/Y
• Regenxbio (RGNX) Q3 2026 · revenue $9.2M · -69% Y/Y
• Interpace Biosciences (IDXG) Q2 2026 · revenue $9.1M · -1% Y/Y
• Earth Science Tech (ETST) Q1 FY27 · revenue $9.0M · +3% Y/Y
• Arcus Biosciences (RCUS) Q3 2026 · revenue $9.0M · -65% Y/Y
• Cumberland Pharmaceuticals (CPIX) Q2 2026 · revenue $8.8M · -19% Y/Y
• Precision Optics (POCI) Q4 FY26 · revenue $8.8M · +42% Y/Y
• Lftd Partners (LIFD) Q2 2026 · revenue $8.7M · -16% Y/Y
• Utah Medical Products (UTMD) Q2 2026 · revenue $8.5M · -14% Y/Y
• C4 Therapeutics (CCCC) Q3 2026 · revenue $8.5M · -25% Y/Y
• American Shared Hospital Services (AMS) Q2 2026 · revenue $8.4M · +19% Y/Y
• BioStem Technologies (BSEM) Q2 2026 · revenue $7.9M · -28% Y/Y
• Cue Biopharma (CUE) Q2 2026 · revenue $7.9M · +167% Y/Y
• Cryo Cell International (CCEL) Q3 FY26 · revenue $7.8M · 0% Y/Y
• Stereotaxis (STXS) Q2 2026 · revenue $7.7M · -13% Y/Y
• Scilex Holding (SCLX) Q2 2026 · revenue $7.6M · -23% Y/Y
• Aquestive Therapeutics (AQST) Q3 2026 · revenue $7.6M · -41% Y/Y
• Xenon Pharmaceuticals (XENE) Q1 2025 · revenue $7.5M
• Praxis Precision Medicines (PRAX) Q4 2024 · revenue $7.5M · 14× Y/Y
• QT Imaging Holdings (QTI) Q2 2026 · revenue $7.4M · +103% Y/Y
• Leef Brands (LEEEF) Q2 2026 · revenue $7.3M · -16% Y/Y
• Retractable Technologies (RVP) Q2 2026 · revenue $7.2M · -31% Y/Y
• Immucell (ICCC) Q2 2026 · revenue $7.2M · +12% Y/Y
• Intellia Therapeutics (NTLA) Q3 2026 · revenue $7.2M · -48% Y/Y
• Whitehawk Therapeutics (WHWK) Q1 2025 · revenue $7.1M · +34% Y/Y
• Veru (VERU) Q4 FY24 · revenue $6.7M · +72% Y/Y
• Lifeward (LFWD) Q2 2026 · revenue $6.6M · +16% Y/Y
• Sonoma Pharmaceuticals (SNOA) Q1 FY27 · revenue $6.4M · +60% Y/Y
• Emmaus Life Sciences (EMMA) Q2 2026 · revenue $6.3M · +124% Y/Y
• Generate Biomedicines (GENB) Q2 2026 · revenue $6.3M · -38% Y/Y
• Alpha Cognition (ACOG) Q2 2026 · revenue $6.1M · +268% Y/Y
• Verrica Pharmaceuticals (VRCA) Q2 2026 · revenue $5.9M · -54% Y/Y
• Premier Air Charter Holdings (PREM) Q2 2026 · revenue $5.8M · -22% Y/Y
• Prelude Therapeutics (PRLD) Q2 2026 · revenue $5.7M
• Nephros (NEPH) Q3 2026 · revenue $5.6M · +18% Y/Y
• Taysha Gene Therapies (TSHA) Q4 2025 · revenue $5.5M · +171% Y/Y
• Celularity (CELU) Q2 2026 · revenue $5.4M · -5% Y/Y
• uniQure N.V. (QURE) Q3 2026 · revenue $5.2M · +40% Y/Y
• DarioHealth (DRIO) Q2 2026 · revenue $5.2M · -4% Y/Y
• Vivos Therapeutics (VVOS) Q2 2026 · revenue $5.2M · +35% Y/Y
• Surrozen (SRZN) Q2 2026 · revenue $5.0M · +409% Y/Y
• Allogene Therapeutics (ALLO) Q2 2026 · revenue $4.6M
• Zymeworks (ZYME) Q2 2026 · revenue $4.6M · -91% Y/Y
• Equillium (EQ) Q4 2024 · revenue $4.4M · -52% Y/Y
• Biotricity (BTCY) Q1 FY27 · revenue $4.3M · +10% Y/Y
• Marpai (MRAI) Q2 2026 · revenue $4.2M · -10% Y/Y
• AbCellera Biologics (ABCL) Q2 2026 · revenue $4.0M · -76% Y/Y
• Immunome (IMNM) Q2 2025 · revenue $4.0M · +70% Y/Y
• Voyager Therapeutics (VYGR) Q3 2026 · revenue $4.0M · -70% Y/Y
• Hyperfine (HYPR) Q2 2026 · revenue $3.9M · +45% Y/Y
• Escalon Medical (ESMC) Q4 FY26 · revenue $3.9M · +50% Y/Y
• Charlie's Holdings (CHUC) Q2 2026 · revenue $3.8M · +116% Y/Y
• 4D Molecular Therapeutics (FDMT) Q2 2026 · revenue $3.8M · 252× Y/Y
• Kyntra Bio (KYNB) Q1 2026 · revenue $3.7M · +36% Y/Y
• Nexgel (NXGL) Q2 2026 · revenue $3.7M · +28% Y/Y
• CapsoVision (CV) Q2 2026 · revenue $3.6M · +10% Y/Y
• Spectral AI (MDAI) Q2 2026 · revenue $3.5M · -30% Y/Y
• Lenz Therapeutics (LENZ) Q3 2026 · revenue $3.4M · -73% Y/Y
• Aktis Oncology (AKTS) Q2 2026 · revenue $3.4M · +111% Y/Y
• LogicMark (LGMK) Q2 2026 · revenue $3.3M · +17% Y/Y
• Medinotec (MDNC) Q2 FY27 · revenue $3.2M · -1% Y/Y
• Atrium Therapeutics (RNA) Q2 2026 · revenue $3.0M · -22% Y/Y
• CV Sciences (CVSI) Q2 2026 · revenue $3.0M · -18% Y/Y
• Picard Medical (PMI) Q2 2026 · revenue $3.0M · +39% Y/Y
• Milestone Scientific (MLSS) Q2 2026 · revenue $2.8M · +22% Y/Y
• Aligos Therapeutics (ALGS) Q3 2026 · revenue $2.8M · +282% Y/Y
• X4 Pharmaceuticals (XFOR) Q3 2026 · revenue $2.8M · +75% Y/Y
• Connect Biopharma Holdings (CNTB) Q2 2026 · revenue $2.8M · 58× Y/Y
• Traws Pharma (TRAW) Q2 2025 · revenue $2.7M · 48× Y/Y
• International Stem Cell (ISCO) Q2 2026 · revenue $2.7M · +9% Y/Y
• EBR Systems (NONE.) Q2 2026 · revenue $2.6M · 16× Y/Y
• Evofem Biosciences (EVFM) Q2 2026 · revenue $2.6M · -45% Y/Y
• Tvardi Therapeutics (TVRD) Q1 2025 · revenue $2.6M · +20% Y/Y
• Elutia (ELUT) Q2 2026 · revenue $2.4M · -12% Y/Y
• Lipocine (LPCN) Q3 2026 · revenue $2.3M · 20× Y/Y
• Sensus Healthcare (SRTS) Q2 2026 · revenue $2.3M · -69% Y/Y
• Sintx Technologies (SINT) Q3 2026 · revenue $2.2M · +953% Y/Y
• Invo Fertility (IVF) Q2 2026 · revenue $2.2M · +17% Y/Y
• Cardiff Lexington (CDIX) Q2 2026 · revenue $2.2M · -23% Y/Y
• Fate Therapeutics (FATE) Q2 2026 · revenue $2.1M · +9% Y/Y
• Healthy Extracts (HYEX) Q2 2026 · revenue $2.1M · +113% Y/Y
• Aspira Women's Health (AWHL) Q2 2026 · revenue $2.0M · -15% Y/Y
• Neuroone Medical Technologies (NMTC) Q3 FY26 · revenue $2.0M · +16% Y/Y
• Nuwellis (NUWE) Q2 2026 · revenue $2.0M · +14% Y/Y
• Ocugen (OCGN) Q3 2026 · revenue $2.0M · +11% Y/Y
• Neuraxis (NRXS) Q2 2026 · revenue $1.9M · +116% Y/Y
• Scribe Therapeutics (SCTX) Q2 2026 · revenue $1.9M · -61% Y/Y
• Camp4 Therapeutics (CAMP) Q3 2026 · revenue $1.9M · +139% Y/Y
• Functional Brands (MEHA) Q2 2026 · revenue $1.9M · +2% Y/Y
• DataMeds AI (MEDS) Q2 2026 · revenue $1.8M · -77% Y/Y
• InspireMD (NSPR) Q2 2026 · revenue $1.8M · -0.4% Y/Y
• Nuo Therapeutics (AURX) Q2 2026 · revenue $1.8M · +153% Y/Y
• Beyond Air (XAIR) Q1 FY27 · revenue $1.8M · +0.5% Y/Y
• Rani Therapeutics Holdings (RANI) Q2 2026 · revenue $1.7M
• AtaiBeckley Q2 2026 · revenue $1.7M · +137% Y/Y
• Tenaya Therapeutics (TNYA) Q3 2026 · revenue $1.7M
• CytomX Therapeutics (CTMX) Q3 2026 · revenue $1.7M · -72% Y/Y
• Alumis (ALMS) Q2 2026 · revenue $1.7M · -38% Y/Y
• Caribou Biosciences (CRBU) Q3 2026 · revenue $1.6M · -27% Y/Y
• CG Oncology (CGON) Q3 2026 · revenue $1.6M · -4% Y/Y
• DBV Technologies S.A. (DBVT) Q3 2026 · revenue $1.6M · -43% Y/Y
• Vsee Health (VSEE) Q2 2026 · revenue $1.6M · -54% Y/Y
• Polomar Health Services (PMHS) Q2 2026 · revenue $1.5M · 279× Y/Y
• Pacific Health Care Organization (PFHO) Q3 2026 · revenue $1.5M · -5% Y/Y
• Outlook Therapeutics (OTLK) Q3 FY25 · revenue $1.5M
• Citius Oncology (CTOR) Q3 FY26 · revenue $1.5M
• Citius Pharmaceuticals (CTXR) Q3 FY26 · revenue $1.5M
• Aclaris Therapeutics (ACRS) Q3 2026 · revenue $1.5M · -55% Y/Y
• Vistagen Therapeutics (VTGN) Q1 FY27 · revenue $1.5M · +505% Y/Y
• Lucid Diagnostics (LUCD) Q2 2026 · revenue $1.5M · +27% Y/Y
• Roivant Sciences (ROIV) Q1 FY27 · revenue $1.4M · -34% Y/Y
• Target Group (CBDY) Q2 2026 · revenue $1.4M · +11% Y/Y
• Elite Health Systems (EHSI) Q2 2026 · revenue $1.3M
• Pmgc Holdings (ELAB) Q2 2026 · revenue $1.3M
• Inhibrx Biosciences (INBX) Q2 2025 · revenue $1.3M · 13× Y/Y
• Korro Bio (KRRO) Q4 2025 · revenue $1.3M · -43% Y/Y
• Tenon Medical (TNON) Q2 2026 · revenue $1.3M · +127% Y/Y
• Biomerica (BMRA) Q1 FY27 · revenue $1.3M · -8% Y/Y
• Metagenomi Therapeutics (MGX) Q1 2026 · revenue $1.2M · -70% Y/Y
• Jaguar Health (JAGX) Q2 2026 · revenue $1.2M · -59% Y/Y
• Ionetix Q2 2026 · revenue $1.2M · +9% Y/Y
• Ensysce Biosciences (ENSC) Q2 2026 · revenue $1.2M · -15% Y/Y
• Intelligent Bio Solutions (INBS) Q4 FY26 · revenue $1.1M · +36% Y/Y
• NRX Pharmaceuticals (NRXP) Q2 2026 · revenue $1.1M
• Lineage Cell Therapeutics (LCTX) Q2 2026 · revenue $1.1M · -61% Y/Y
• RenovoRx (RNXT) Q3 2026 · revenue $1.1M · +301% Y/Y
• TScan Therapeutics (TCRX) Q2 2026 · revenue $1.1M · -66% Y/Y
• Crescent Biopharma (CBIO) Q1 2026 · revenue $1.0M
• Korsana Biosciences (KRSA) Q4 2025 · revenue $1.0M · -43% Y/Y
• Flyte Aviation (VTAK) Q2 2026 · revenue $1.0M · +381% Y/Y
• Arbutus Biopharma (ABUS) Q2 2026 · revenue $1.0M · -91% Y/Y
• ProPhase Labs (PRPH) Q2 2026 · revenue $1.0M · -19% Y/Y
• Innovative Eyewear (LUCYW) Q2 2026 · revenue $1.0M · +74% Y/Y
• Anteris Technologies Global (AVR) Q2 2026 · revenue $1.0M · +63% Y/Y
• Shattuck Labs (STTK) Q3 2025 · revenue $1.0M · -67% Y/Y
• Dyadic International (DYAI) Q2 2026 · revenue $1.0M · -0.6% Y/Y
• China Pharma Holdings (CPHI) Q2 2026 · revenue $948K · -8% Y/Y
• Entrada Therapeutics (TRDA) Q3 2026 · revenue $905K · -44% Y/Y
• TherapeuticsMD (TXMD) Q2 2026 · revenue $869K · -9% Y/Y
• ADM Tronics Unlimited (ADMT) Q1 FY27 · revenue $866K · -11% Y/Y
• GeoVax Labs (GOVX) Q2 2025 · revenue $852K · +184% Y/Y
• QHSLab (USAQ) Q2 2026 · revenue $847K · +40% Y/Y
• Prime Medicine (PRME) Q4 2025 · revenue $838K · -62% Y/Y
• Northwest Biotherapeutics (NWBO) Q2 2026 · revenue $807K · +516% Y/Y
• ImageneBio (IMA) Q1 2025 · revenue $800K
• Bio Essence (BIOE) Q2 2026 · revenue $795K · +207% Y/Y
• Upstream Bio (UPB) Q2 2026 · revenue $773K · -18% Y/Y
• Opus Genetics (IRD) Q2 2026 · revenue $755K · -74% Y/Y
• Ovid Therapeutics (OVID) Q2 2026 · revenue $733K · -88% Y/Y
• Spruce Biosciences (SPRB) Q4 2024 · revenue $697K · -76% Y/Y
• Xenetic Biosciences (XBIO) Q2 2026 · revenue $661K · +12% Y/Y
• Longduoduo (LDDD) Q4 FY26 · revenue $631K · -33% Y/Y
• Atara Biotherapeutics (ATRA) Q2 2026 · revenue $630K · -96% Y/Y
• Stemtech (STEK) Q2 2026 · revenue $629K · -10% Y/Y
• Prothena Corp Public (PRTA) Q3 2026 · revenue $620K · -74% Y/Y
• SeaStar Medical Holding (ICU) Q2 2026 · revenue $615K · +82% Y/Y
• Seres Therapeutics (MCRB) Q3 2026 · revenue $593K · +69% Y/Y
• Vitro Biopharma Q3 FY26 · revenue $570K · -6% Y/Y
• Milestone Pharmaceuticals (MIST) Q2 2026 · revenue $559K
• Family Office of America (FOFA) Q2 2026 · revenue $533K
• Arvinas (ARVN) Q3 2026 · revenue $500K · -99% Y/Y
• Palisade Bio (PALI) Q2 2026 · revenue $500K
• Mereo BioPharma Group (MREO) Q2 2025 · revenue $500K
• Adia Med (ADIA) Q2 2026 · revenue $485K · +311% Y/Y
• Medicinova (MNOV) Q2 2026 · revenue $458K · +241% Y/Y
• Attovia Therapeutics (ATTO) Q2 2026 · revenue $450K
• NutriBand (NTRB) Q2 FY27 · revenue $438K · -30% Y/Y
• Silence Therapeutics (SLN) Q1 2026 · revenue $422K · +197% Y/Y
• Vycor Medical (VYCO) Q2 2026 · revenue $418K · -16% Y/Y
• Harvard Apparatus Regenerative Technology (HRGN) Q2 2026 · revenue $414K · +31% Y/Y
• Cerenome (CNSY) Q2 2026 · revenue $411K · -70% Y/Y
• Humacyte (HUMA) Q2 2026 · revenue $406K · +35% Y/Y
• Volitionrx (VNRX) Q2 2026 · revenue $399K · -2% Y/Y
• Pulse Biosciences (PLSE) Q3 2026 · revenue $395K · +359% Y/Y
• Relay Therapeutics (RLAY) Q2 2026 · revenue $350K · -48% Y/Y
• Scienture Holdings (SCNX) Q2 2026 · revenue $344K
• PetVivo Holdings (PETV) Q1 FY27 · revenue $338K · +14% Y/Y
• Pluri (PLUR) Q4 FY26 · revenue $335K · -16% Y/Y
• Femasys (FEMY) Q2 2026 · revenue $332K · -19% Y/Y
• IGC Pharma (IGC) Q3 2026 · revenue $328K · +72% Y/Y
• OSR Health (OSRH) Q2 2026 · revenue $316K · -72% Y/Y
• Beam Therapeutics (BEAM) Q3 2026 · revenue $307K · -97% Y/Y
• Palatin Technologies (PTN) Q4 FY26 · revenue $301K
• Theriva Biologics (TOVX) Q1 2026 · revenue $300K
• BioAge Labs (BIOA) Q3 2026 · revenue $298K · -86% Y/Y
• Longeveron (LGVN) Q2 2026 · revenue $287K · -9% Y/Y
• Dianthus Therapeutics (DNTH) Q4 2025 · revenue $284K · -79% Y/Y
• Cannapharmarx (CPMD) Q2 2026 · revenue $276K · +19% Y/Y
• Spero Therapeutics (SPRO) Q1 2026 · revenue $258K · -96% Y/Y
• Oncotelic Therapeutics (OTLC) Q2 2026 · revenue $250K
• HealthLynked (HLYK) Q2 2026 · revenue $250K · -58% Y/Y
• Rafael Holdings (RFL) Q4 FY26 · revenue $244K · -30% Y/Y
• Coya Therapeutics (COYA) Q2 2026 · revenue $244K · +49% Y/Y
• Microbot Medical (MBOT) Q2 2026 · revenue $241K
• ENvue Medical (FEED) Q2 2026 · revenue $239K · -52% Y/Y
• Insight Molecular Diagnostics (IMDX) Q2 2026 · revenue $239K · -54% Y/Y
• Scynexis (SCYX) Q2 2026 · revenue $235K · -83% Y/Y
• Decoy Therapeutics (DCOY) Q2 2026 · revenue $228K
• BullFrog AI Holdings (BFRG) Q2 2026 · revenue $215K · +548% Y/Y
• 60 Degrees Pharmaceuticals (SXTP) Q2 2026 · revenue $208K · +106% Y/Y
• aTYR Pharma (ATYR) Q3 2025 · revenue $190K
• Dare Bioscience (DARE) Q2 2026 · revenue $188K
• BioXcel Therapeutics (BTAIQ) Q2 2026 · revenue $182K · +52% Y/Y
• Co-Diagnostics (CODX) Q2 2026 · revenue $166K · +2% Y/Y
• Prokidney (PROK) Q2 2026 · revenue $150K · -32% Y/Y
• Parabilis Medicines (PBLS) Q2 2026 · revenue $148K
• HCW Biologics (HCWB) Q2 2026 · revenue $136K · 21× Y/Y
• Serina Therapeutics (SER) Q2 2025 · revenue $130K · +155% Y/Y
• Positron (POSC) Q2 2026 · revenue $112K · -7% Y/Y
• Agape ATP (ATPC) Q2 2026 · revenue $109K · -77% Y/Y
• Cocrystal Pharma (COCP) Q2 2026 · revenue $105K
• Cardiff Oncology (CRDF) Q2 2026 · revenue $104K · -14% Y/Y
• Dogwood Therapeutics (DWTX) Q3 2026 · revenue $100K
• iBio (IBIO) Q1 FY26 · revenue $100K
• Accustem Sciences (ACUT) Q2 2026 · revenue $98K
• Yarrow Bioscience (YARW) Q2 2026 · revenue $97K · +41% Y/Y
• Orchestra BioMed Holdings (OBIO) Q2 2026 · revenue $88K · -90% Y/Y
• BioCorRx (BICX) Q2 2026 · revenue $88K · -51% Y/Y
• Cartesian Therapeutics (RNAC) Q1 2026 · revenue $78K · -93% Y/Y
• BioNexus Gene Lab (BGLC) Q2 2026 · revenue $76K · -97% Y/Y
• Mangoceuticals (MGRX) Q2 2026 · revenue $69K · -59% Y/Y
• Envoy Medical (COCH) Q3 2026 · revenue $66K · +57% Y/Y
• Inovio Pharmaceuticals (INO) Q1 2025 · revenue $65K
• HWH International (ESYN) Q2 2026 · revenue $64K · -79% Y/Y
• Aspire-Lakewood Holdings (ASBP) Q2 2026 · revenue $63K
• Regen BioPharma (RGBP) Q3 FY26 · revenue $59K · 0% Y/Y
• Avalo Therapeutics (AVTX) Q4 2025 · revenue $59K · -69% Y/Y
• Clene (CLNN) Q3 2026 · revenue $56K · +273% Y/Y
• Global Innovative Platforms (GIPL) Q3 FY26 · revenue $51K
• Sera Prognostics (SERA) Q3 2026 · revenue $42K · +162% Y/Y
• Entera Bio (ENTX) Q1 2025 · revenue $42K
• Neonc Technologies Holdings (NTHI) Q1 2025 · revenue $40K · -7% Y/Y
• Vivos (RDGL) Q2 2026 · revenue $36K · +143% Y/Y
• Nutra Pharma (NPHC) Q2 2026 · revenue $34K · -59% Y/Y
• Aclarion (ACON) Q3 2026 · revenue $34K · +78% Y/Y
• PAVmed (PAVM) Q2 2026 · revenue $33K · +450% Y/Y
• Lunai Bioworks (LNAI) Q4 FY26 · revenue $31K
• Vyome Holdings (HIND) Q2 2026 · revenue $27K · -46% Y/Y
• America Great Health (AAGH) Q3 FY26 · revenue $26K · -53% Y/Y
• AIM ImmunoTech (AIM) Q2 2026 · revenue $26K · +4% Y/Y
• Altimmune (ALT) Q4 2025 · revenue $26K · +420% Y/Y
• Allarity Therapeutics (ALLR) Q1 2026 · revenue $25K
• Jupiter Neurosciences (JUNS) Q2 2026 · revenue $24K
• Celldex Therapeutics (CLDX) Q2 2026 · revenue $22K · -97% Y/Y
• VivoSim Labs (VIVS) Q1 FY27 · revenue $18K · -51% Y/Y
• Onconetix (ONCO) Q2 2026 · revenue $17K · -84% Y/Y
• Senti Biosciences Holdings (SNTI) Q2 2026 · revenue $17K
• Nexalin Technology (NXL) Q2 2026 · revenue $12K · -83% Y/Y
• CervoMed (CRVO) Q4 2025 · revenue $9K · -100% Y/Y
• Skinvisible (SKVI) Q2 2026 · revenue $5K · 0% Y/Y
• Bolt Biotherapeutics (BOLT) Q2 2026 · revenue $5K · -100% Y/Y
• Bioadaptives (BDPT) Q2 2026 · revenue $5K · +55% Y/Y
• Naploy (NPLY) Q4 FY26 · revenue $5K · +39% Y/Y
• Essence Array Q2 FY27 · revenue $5K
• Cardio Diagnostics Holdings (CDIO) Q3 2026 · revenue $4K · +26% Y/Y
• Lyell Immunopharma (LYEL) Q3 2026 · revenue $3K · -80% Y/Y
• Impact Biomedical (IBO) Q2 2026 · revenue $3K · -57% Y/Y
• Pulmatrix (PULM) Q4 2024 · revenue $3K · -100% Y/Y
• Fractyl Health (GUTS) Q4 2024 · revenue $3K · -57% Y/Y
• Medical Exercise (MDXR) Q1 FY27 · revenue $1K
• Talphera (TLPH) Q3 2025 · revenue $1K
• China Foods Holdings (CFOO) Q2 2026 · revenue $0K · -100% Y/Y